Shanghai Shyndec's subsidiary secures drug registration certificate

Shanghai Shyndec Pharmaceutical (SSE:600420) announced that its wholly-owned subsidiary, Sinopharm Rong Sheng Pharmaceutical, has been granted a drug registration certificate for Tofacitinib Citrate Tablets by the National Medical Products Administration. Classified as a Category 4 chemical drug, the tablet is a new type of oral protein tyrosine kinase inhibitor indicated for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. According to market data, Tofacitinib Citrate Tablets saw CNY 477 million in sales across public medical institutions in China in 2024. Sinopharm Rong Sheng invested approximately CNY 15.54 million in the research and development of the tablet. The company notes that sales are subject to policy and market risks.